BOTHELL, Wash.--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has filed an investigational new drug (IND) application to conduct a Phase 1 clinical trial for its lead compound ACU-02 with the U.S. Food and Drug Administration (FDA). The filing follows a successful pre-IND meeting in Washington D.C. where the company reviewed its current pre-clinical efficacy and safety data as well as development plans with FDA.
